Top Markets
Coin of the day
Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLI
Classement en actions #31761
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Prix de l'action
$1.10
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$12.14M
Changement (1 jour)
11.11%
Changement (1 an)
77.42%
Pays
US
Échange Brainstorm Cell Therapeutics Inc. (BCLI)

Catégorie

Ratio P/S pour Brainstorm Cell Therapeutics Inc. (BCLI)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Brainstorm Cell Therapeutics Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Brainstorm Cell Therapeutics Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
- -
KR